Under construction – not a live service
Sign in
Taking peoplePhase 3

Tests lenbelintide added to weight-loss medicines in adults with excess weight

Tests lenbelintide against placebo alongside incretin medicines in adults with obesity or overweight.

Key facts

Who runs it
AstraZeneca
Where
Beijing, Changchun, Chengdu, Guangzhou, Huzhou, Nanjing, and Ningbo, ChinaSee the 7 sitesAlso in 10 other countries, 79 sites
Registry title
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Status
Recruiting
Phase
Phase 3
People taking part
500 people, planned
Started
24 Aug 2026
Expected to end
9 Aug 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Lenbelintide
  • Placebo
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity or overweight who already take a stable dose of an incretin-based weight medicine. People with type 2 diabetes can also join.

Age
18 years or older
Sex
All sexes and gender identities can join.
Disease stage
BMI of 30 kg/m2 or more, or BMI of 27 kg/m2 or more with at least one weight-related condition. Examples are high blood pressure, sleep apnoea or knee osteoarthritis. People with type 2 diabetes must have had it for at least 90 days and have HbA1c of 6.0% (42 mmol/mol) to 9.0% (75 mmol/mol).
Earlier treatment
A stable dose of an incretin-based medicine, enough for weight management, for at least 3 months. Stable body weight (3% change or less) for at least 3 months. At least one self-reported failed attempt to lose weight.
Biomarker or test result
For people with type 2 diabetes: HbA1c of 6.0% (42 mmol/mol) to 9.0% (75 mmol/mol) at Screening.

Main reasons for not taking part

  • Obesity mainly caused by other hormone disorders
  • Type 1 diabetes
  • Significant liver or bile duct disease, or ALT or AST of 3.0 × ULN or more
  • Bilirubin above 1.5 × ULN (except known Gilbert's Syndrome)
  • Insulin for type 2 diabetes within 3 months before screening

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Males \& females (inclusive of all gender identities) age ≥18 years
  • BMI ≥ 30 kg/m2 OR BMI ≥ 27 kg/m2 with at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence
  • For participants with T2DM only:; Diagnosed with T2DM ≥ 90 days prior to Screening; HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤9.0% (75 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent and/or incretin-based medication
  • Receiving a stable dose of incretin- based medications at a dose level that is sufficient for chronic weight management for at least 3 months prior to Screening and Randomisation
  • Stable body weight (≤ 3% body weight change) for at least 3 months prior to Randomisation
  • History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime

Who cannot take part

  • Use of insulin therapy for T2DM within 3 months prior to screening
  • Obesity primarily caused by other endocrine disorders
  • Type 1 diabetes mellitus
  • Significant hepatobiliary disease and/or any of the following results at Screening:; ALT ≥ 3.0 × ULN; AST ≥ 3.0 × ULN; TBL > 1.5 × ULN (except for cases of known Gilbert's Syndrome)

Where in China

Also in 10 other countries, 79 sites

  • BeijingHospital not named in the registryNot yet recruiting
  • ChangchunHospital not named in the registryNot yet recruiting
  • ChengduHospital not named in the registryNot yet recruiting
  • GuangzhouHospital not named in the registryNot yet recruiting
  • HuzhouHospital not named in the registryNot yet recruiting
  • NanjingHospital not named in the registryNot yet recruiting
  • NingboHospital not named in the registryNot yet recruiting

About the trial

What the trial wants to find out

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.

The 2 groups in the trial

  • AZD6234Treatment being tested

    Treatment: Lenbelintide

  • PlaceboPlacebo, for comparison

    Matching placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus (SELENE 3)
Plain-language title
Tests lenbelintide added to weight-loss medicines in adults with excess weightGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 10 November 2026.
Record updated
9 November 2026